MA52499A - Associations pour le traitement du cancer - Google Patents

Associations pour le traitement du cancer

Info

Publication number
MA52499A
MA52499A MA052499A MA52499A MA52499A MA 52499 A MA52499 A MA 52499A MA 052499 A MA052499 A MA 052499A MA 52499 A MA52499 A MA 52499A MA 52499 A MA52499 A MA 52499A
Authority
MA
Morocco
Prior art keywords
cancer treatment
treatment associations
associations
cancer
treatment
Prior art date
Application number
MA052499A
Other languages
English (en)
French (fr)
Inventor
Scott Boiko
Justin Cidado
Lisa Drew
Theresa Proia
Martin Maryann San
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA52499A publication Critical patent/MA52499A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA052499A 2018-04-30 2019-04-29 Associations pour le traitement du cancer MA52499A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA52499A true MA52499A (fr) 2021-04-14

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052499A MA52499A (fr) 2018-04-30 2019-04-29 Associations pour le traitement du cancer

Country Status (14)

Country Link
US (1) US20210030718A1 (https=)
EP (1) EP3787620A1 (https=)
JP (1) JP2021522246A (https=)
KR (1) KR20210005182A (https=)
CN (1) CN112040944A (https=)
AU (1) AU2019263026B2 (https=)
BR (1) BR112020022020A2 (https=)
CA (1) CA3097486A1 (https=)
EA (1) EA202092540A1 (https=)
MA (1) MA52499A (https=)
MX (1) MX2020011453A (https=)
SG (1) SG11202010528XA (https=)
TW (1) TW202014184A (https=)
WO (1) WO2019211721A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
JP2023510135A (ja) * 2019-12-18 2023-03-13 ゼノ マネジメント，インコーポレイテッド 大環状化合物
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
CA2956550A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
PT3445767T (pt) * 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
US20210030718A1 (en) 2021-02-04
EP3787620A1 (en) 2021-03-10
CN112040944A (zh) 2020-12-04
CA3097486A1 (en) 2019-11-07
JP2021522246A (ja) 2021-08-30
AU2019263026B2 (en) 2022-06-30
EA202092540A1 (ru) 2021-03-17
WO2019211721A1 (en) 2019-11-07
MX2020011453A (es) 2020-12-07
BR112020022020A2 (pt) 2021-02-02
SG11202010528XA (en) 2020-11-27
KR20210005182A (ko) 2021-01-13
TW202014184A (zh) 2020-04-16
AU2019263026A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (en) Combination therapy for cancer treatment
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3474854A4 (en) CANCER TREATMENT COMBINATIONS
EP3285773A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3359192A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
MA47408A (fr) Traitement du cancer
EP3359255A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
MA52627A (fr) Traitement du cancer
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3681498A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3733175A4 (en) THERAPEUTICS AGAINST CANCER
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3793544A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3787625A4 (en) METHODS OF TREATMENT OF CANCER
EP3411073A4 (en) Combinations to treat cancer
EP3773625A4 (en) METHODS AND MATERIALS FOR TREATMENT OF CANCER